Non-antibiotic therapy for Clostridioides difficile infection: A review

被引：20

作者：

Yang, Jingpeng ^{[1
,2
]}

Yang, Hong ^{[1
,2
]}

机构：

[1] Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Shanghai, Peoples R China

[2] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai, Peoples R China

来源：

CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES | 2019年 / 56卷 / 07期

关键词：

Clostridioides difficile infection; antibiotics; probiotics; fecal microbiota transplantation; FECAL MICROBIOTA TRANSPLANTATION; LACTIC-ACID BACTERIA; DOUBLE-BLIND; TOXIN PRODUCTION; GUT MICROBIOTA; PHAGE THERAPY; RIBOTYPE; 027; PROBIOTICS; PREVENTION; DIARRHEA;

D O I：

10.1080/10408363.2019.1648377

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Clostridioides difficile infection (CDI) is a common infectious disease that is mainly caused by antibiotics. Antibiotic therapy is still the dominant treatment for CDI, although it is accompanied by side effects. Probiotics, fecal microbiota transplantation (FMT), engineered microorganisms, bacteriophages, diet, natural active substances, nanoparticles and compounds are examples of emerging non-antibiotic therapies that have received a great amount of attention. In this review, we collected data about different non-antibiotic therapies for CDI and provided a comprehensive analysis and detailed comparison of these therapies. The mechanism of action, therapeutic efficacy, and the strengths and weaknesses of these non-antibiotic therapies have been investigated to provide a basis for the reasonable alternative of non-antibiotic therapies for CDI. In summary, probiotics and FMT are currently the best choice for non-antibiotic therapy for CDI.

引用

页码：493 / 509

页数：17

共 148 条

[1] Kinetics of Phage-Mediated Biocontrol of Bacteria [J].

Abedon, Stephen T. .

FOODBORNE PATHOGENS AND DISEASE, 2009, 6 (07) :807-815

[2] Clostridium difficile colitis: pathogenesis and host defence [J].

Abt, Michael C. ;

McKenney, Peter T. ;

Pamer, Eric G. .

NATURE REVIEWS MICROBIOLOGY, 2016, 14 (10) :609-620

[3] Resistance to antibiotics: Are we in the post-antibiotic era? [J].

Alanis, AJ .

ARCHIVES OF MEDICAL RESEARCH, 2005, 36 (06) :697-705

[4] Clostridium difficile infection [J].

Alcala Hernandez, Luis ;

Reigadas Ramirez, Elena ;

Bouza Santiago, Emilio .

MEDICINA CLINICA, 2017, 148 (10) :456-463

[5] Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile [J].

Aldape, Michael John ;

Heeney, Dustin Delaney ;

Bryant, Amy Evelyn ;

Stevens, Dennis Leroy .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (01) :153-159

[6] Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile [J].

Aldape, Michael John ;

Packham, Aaron Eugene ;

Nute, Drew William ;

Bryant, Amy Evelyn ;

Stevens, Dennis Leroy .

JOURNAL OF MEDICAL MICROBIOLOGY, 2013, 62 :741-747

[7] Inhibition of Clostridium difficile by natural herbal extracts [J].

Aljarallah, Khalid M. .

JOURNAL OF TAIBAH UNIVERSITY MEDICAL SCIENCES, 2016, 11 (05) :427-431

[8] Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial [J].

Allen, Stephen J. ;

Wareham, Kathie ;

Wang, Duolao ;

Bradley, Caroline ;

Hutchings, Hayley ;

Harris, Wyn ;

Dhar, Anjan ;

Brown, Helga ;

Foden, Alwyn ;

Gravenor, Michael B. ;

Mack, Dietrich .

LANCET, 2013, 382 (9900) :1249-1257

[9]

Allen-Vercoe Emma, 2012, Can J Gastroenterol, V26, P457

[10]

Aranda CMA, 2010, ANTIMICROBIAL RESISTANCE IN DEVELOPING COUNTRIES, P491, DOI 10.1007/978-0-387-89370-9_28

← 1 2 3 4 5 6 7 8 9 10 →